|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 1991; 17:590-598 © 1991 by the American College of Cardiology Foundation |
Medical Division, Burroughs Wellcome Co., Research Triangle Park, North Carolina 27709.
An observational surveillance study was conducted to monitor the safety and effectiveness of treatment with Digoxin Immune Fab (Ovine) (Digibind) in patients with digitalis intoxication. Before April 1986, a relatively limited number of patients received treatment with digoxin-specific Fab fragments through a multicenter clinical trial. Beginning with commercial availability in July 1986, this study sought additional, voluntarily reported clinical data pertaining to treatment through a 3 week follow-up. The study included 717 adults who received Digoxin Immune Fab (Ovine). Most patients were greater than or equal to 70 years old and developed toxicity during maintenance dosing with digoxin. Fifty percent of patients were reported to have a complete response to treatment, 24% a partial response and 12% no response. The response for 14% of patients was not reported or reported as uncertain. Six patients (0.8%, 95% confidence interval 0.3% to 1.8%) had an allergic reaction to digoxin-specific antibody fragments. Three of the six had a history of allergy to antibiotic drugs. Twenty patients (2.8%, 95% confidence interval 1.7% to 4.3%) developed recrudescent toxicity. Risk of recrudescent toxicity increased sixfold when less than 50% of the estimated dose of antibody was administered. A total of 215 patients experienced posttreatment adverse events. The events for 163 patients (76%) were judged to result from manifestations of underlying disease and thus considered unrelated to Fab treatment. Digoxin-specific antibody fragments were generally well tolerated and clinically effective in patients judged by treating physicians to have potentially life-threatening digitalis intoxication.
This article has been cited by other articles:
|
|
 |
|
  D. P. Betten, R. B. Vohra, M. D. Cook, M. J. Matteucci, and R. F. Clark Antidote use in the critically ill poisoned patient. J Intensive Care Med, September 1, 2006; 21(5): 255 - 277. [Abstract] [PDF]
|
|
|
|
 |
|
 D. N. Juurlink, M. A. McGuigan, T. W. Paton, and D. A. Redelmeier Availability of antidotes at acute care hospitals in Ontario Can. Med. Assoc. J., July 1, 2001; 165(1): 27 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. DiDomenico, S. M. Walton, C. A. Sanoski, and J. L. Bauman Analysis of the Use of Digoxin Immune Fab for the Treatment of Non-Life-Threatening Digoxin Toxicity Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(2): 77 - 85. [Abstract] [PDF]
|
|
|
|
 |
|
 W. J. Ball Jr., R. Kasturi, P. Dey, M. Tabet, S. O'Donnell, D. Hudson, and D. Fishwild Isolation and Characterization of Human Monoclonal Antibodies to Digoxin J. Immunol., August 15, 1999; 163(4): 2291 - 2298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Hauptman and R. A. Kelly Digitalis Circulation, March 9, 1999; 99(9): 1265 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Proksch, W. B. Gentry, and S. M. Owens Pharmacokinetic Mechanisms for Obtaining High Renal Coelimination of Phencyclidine and a Monoclonal Antiphencyclidine Antigen-Binding Fragment of Immunoglobulin G in the Rat J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 616 - 624. [Abstract] [Full Text]
|
|
|
|
|
|
J. S. Hardin, W. D. Wessinger, J. W. Proksch, and S. M. Owens Pharmacodynamics of a Monoclonal Antiphencyclidine Fab with Broad Selectivity for Phencyclidine-Like Drugs1 J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1113 - 1122. [Abstract] [Full Text]
|
|
|
|
|
|
G. Rivière, V. Choumet, B. Saliou, M. Debray, and C. Bon Absorption and Elimination of Viper Venom after Antivenom Administration J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 490 - 495. [Abstract] [Full Text]
|
|
|
|
|
|
G. Rivière, V. Choumet, F. Audebert, A. Sabouraud, M. Debray, J.-M. Scherrmann, and C. Bon Effect of Antivenom on Venom Pharmacokinetics in Experimentally Envenomed Rabbits: Toward an Optimization of Antivenom Therapy J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 1 - 8. [Abstract] [Full Text]
|
|
|
|
 |
|
 IMMUNE THERAPY FOR DIGOXIN TOXICITY IS SAFE AND EFFECTIVE Journal Watch (General), March 8, 1991; 1991(308): 6 - 6. [Full Text]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
